Increased activation and differentiated localization of native and phosphorylated STAT3 in nasal polyps

International Archives of Allergy and Immunology

Volumn 162, Issue 4, 2013, Pages 290-298

  Linke, Robert ^a,c   Pries, Ralph ^a   Könnecke, Michael ^a   Bruchhage, Karl Ludwig ^a   Böscke, Robert ^a   Gebhard, Maximilian ^b   Wollenberg, Barbara ^a  

^a Department of Otorhinolaryngology and Facial Plastic Surgery ^*  (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Chronic rhinosinusitis; JAK STAT pathway; Nasal polyp; Phosphokinase; STAT3

Indexed keywords

STAT3 PROTEIN;

ADULT; AGED; ARTICLE; BASEMENT MEMBRANE; CHRONIC RHINOSINUSITIS; CHRONIC RHINOSINUSITIS WITH NASAL POLYP; CHRONIC SINUSITIS; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE DURATION; DNA MICROARRAY; EPITHELIUM; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NOSE POLYP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; SCORING SYSTEM; TREATMENT FAILURE; TURBINATE; WESTERN BLOTTING;

ADULT; AGED, 80 AND OVER; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL MUCOSA; NASAL POLYPS; PHOSPHORYLATION; RHINITIS; SINUSITIS; STAT3 TRANSCRIPTION FACTOR;

EID: 84885984990     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000353893     Document Type: Article

References (59)

1. Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A, Bousquet PJ, Brozek G, Bruno A, Dahlen SE, Forsberg B, Gunnbjornsdottir M, Kasper L, Kramer U, Kowalski ML, Lange B, Lundback B, Salagean E, Todo-Bom A, Tomassen P, Toskala E, van Drunen CM, Bousquet J, Zuberbier T, Jarvis D, Burney P: Chronic rhinosinusitis in Europe-an underestimated disease. A GA(2) LEN study. Allergy 2011; 66: 1216-1223.
2. Pleis JR, Lucas JW, Ward BW: Summary health statistics for US adults: National Health Interview Survey, 2008. Vital Health Stat 2009; 10: 1-157.
3. Van Crombruggen K, Van Bruaene N, Holtappels G, Bachert C: Chronic sinusitis and rhinitis: clinical terminology 'Chronic Rhinosinusitis' further supported. Rhinology 2010; 48: 54-58.
4. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N, Cervin A, Douglas R, Gevaert P, Georgalas C, Goossens H, Harvey R, Hellings P, Hopkins C, Jones N, Joos G, Kalogjera L, Kern B, Kowalski M, Price D, Riechelmann H, Schlosser R, Senior B, Thomas M, Toskala E, Voegels R, Wang de Y, Wormald PJ: European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl 2012: 3 p preceding table of contents, 1-298.
5. Dietz de Loos DA, Hopkins C, Fokkens WJ: Symptoms in chronic rhinosinusitis with and without nasal polyps. Laryngoscope 2013; 123: 57-63.
6. Zhang N, Holtappels G, Claeys C, Huang G, van Cauwenberge P, Bachert C: Pattern of inflammation and impact of Staphylococcus aureus enterotoxins in nasal polyps from southern China. Am J Rhinol 2006; 20: 445-450.
7. Johansson L, Akerlund A, Holmberg K, Melen I, Bende M: Prevalence of nasal polyps in adults: the Skovde population-based study. Ann Otol Rhinol Laryngol 2003; 112: 625-629.
8. Onerci M, Elsurer C, Guzel E, Dagdeviren A: Distribution of inflammatory cells, adhesion molecules, intermediate filaments, and chemokine receptors in subgroups of nasal polyp patients. Am J Rhinol Allergy 2011; 27:e176-e180.
9. Fruth K, Schramek E, Docter D, Haxel BR, Schneider A, Mann WJ, Brieger J: Dysregulated survivin expression in nasal polyps of individuals with aspirin exacerbated respiratory disease. Am J Rhinol Allergy 2012; 26: 380-384.
10. Bromberg JF: Activation of STAT proteins and growth control. Bioessays 2001; 23: 161-169.
11. Turkson J: STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004; 8: 409-422.
12. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S: Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 1997; 94: 3801-3804.
13. Bromberg JF, Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000; 19: 2468-2473.
14. Darnell JE Jr, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
15. Page BD, Ball DP, Gunning PT: Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin Ther Pat 2011; 21: 65-83.
16. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H: Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008; 118: 3367-3377.
17. Weng L, Dai H, Zhan Y, He Y, Stepaniants SB, Bassett DE: Rosetta error model for gene expression analysis. Bioinformatics 2006; 22: 1111-1121.
18. Lund VJ, Mackay IS: Staging in rhinosinusitus. Rhinology 1993; 31: 183-184.
19. Lund VJ, Kennedy DW: Staging for rhinosinusitis. Otolaryngol Head Neck Surg 1997; 117: 35-40.
20. Baumann I, Plinkert PK, De Maddalena H: Development of a grading scale for the Sino-Nasal Outcome Test-20 German Adapted Version (SNOT-20 GAV). HNO 2008; 56: 784-788.
21. Piccirillo JF, Merritt MG Jr, Richards ML: Psychometric and clinimetric validity of the 20-Item Sino-Nasal Outcome Test (SNOT-20). Otolaryngol Head Neck Surg 2002; 126:41-47.
22. Garavello W, Vigano P, Romagnoli M, Sordo L, Berti E, Tredici G, Gaini RM: Expression of cell cycle regulatory proteins and analysis of apoptosis in normal nasal mucosa and in nasal polyps. Am J Rhinol 2005; 19: 549-553.
23. Peters AT, Kato A, Zhang N, Conley DB, Suh L, Tancowny B, Carter D, Carr T, Radtke M, Hulse KE, Seshadri S, Chandra R, Grammer LC, Harris KE, Kern R, Schleimer RP: Evidence for altered activity of the IL-6 pathway in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2010; 125: 397-403.
24. Zhang T, Cao Q, Wang L, Luo S, Tu Z: Expression and correlation of STAT3 with VEGF in the nasal polyps. Chin J Pathophysiol 2009; 25: 993-997.
25. Cao Q, Zhang T, Jiang L, Wang L, Luo S: Expression and significance of STAT3 and VEGF with MVD in the nasal polyps (in Chinese). Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2010; 24: 641-644, 647.
26. Lacroix JS, Zheng CG, Goytom SH, Landis B, Szalay-Quinodoz I, Malis DD: Histological comparison of nasal polyposis in black African, Chinese and Caucasian patients. Rhinology 2002; 40: 118-121.
27. Cao PP, Li HB, Wang BF, Wang SB, You XJ, Cui YH, Wang DY, Desrosiers M, Liu Z: Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese. J Allergy Clin Immunol 2009; 124: 478-484.
28. Zhang N, Liu S, Lin P, Li X, van Bruaene N, Zhang J, van Zele T, Bachert C: Remodeling and inflammation in Chinese versus white patients with chronic rhinosinusitis. J Allergy Clin Immunol 2010; 125: 507, author reply 507-508.
29. Jiang XD, Li GY, Li L, Dong Z, Zhu DD: The characterization of IL-17A expression in patients with chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy 2011; 25:e171-e175.
30. Nakayama T, Yoshikawa M, Asaka D, Okushi T, Matsuwaki Y, Otori N, Hama T, Moriyama H: Mucosal eosinophilia and recurrence of nasal polyps-new classification of chronic rhinosinusitis. Rhinology 2011; 49: 392-396.
31. Toth L, Vajas A, Csomor P, Berta A, Sziklai I, Karosi T: Optical coherence tomography for biofilm detection in chronic rhinosinusitis with nasal polyposis. Eur Arch Otorhinolaryngol 2013; 270: 555-563.
32. Ponikau JU, Sherris DA, Kephart GM, Adolphson C, Kita H: The role of ubiquitous airborne fungi in chronic rhinosinusitis. Clin Rev Allergy Immunol 2006; 30: 187-194.
33. Bachert C, Zhang N, Patou J, van Zele T, Gevaert P: Role of staphylococcal superantigens in upper airway disease. Curr Opin Allergy Clin Immunol 2008; 8: 34-38.
34. Larsen PL, Tos M: Polyp formation by experimental tubal occlusion in the rat. Acta Otolaryngol 1991; 111: 926-933.
35. Larsen PL, Tos M, Kuijpers W, van der Beek JM: The early stages of polyp formation. Laryngoscope 1992; 102: 670-677.
36. Egwuagu CE: STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine 2009; 47: 149-156.
37. Darnell JE: Validating Stat3 in cancer therapy. Nat Med 2005; 11: 595-596.
38. Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
39. Welte T, Zhang SS, Wang T, Zhang Z, Hesslein DG, Yin Z, Kano A, Iwamoto Y, Li E, Craft JE, Bothwell AL, Fikrig E, Koni PA, Flavell RA, Fu XY: STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci USA 2003; 100: 1879-1884.
40. Mitsuyama K, Matsumoto S, Masuda J, Yamasakii H, Kuwaki K, Takedatsu H, Sata M: Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease. Anticancer Res 2007;27: 3749-3756.
41. Sachse F, Becker K, von Eiff C, Metze D, Rudack C: Staphylococcus aureus invades the epithelium in nasal polyposis and induces IL-6 in nasal epithelial cells in vitro. Allergy 2010; 65: 1430-1437.
42. Bystrom J, Patel SY, Amin K, Bishop-Bailey D: Dissecting the role of eosinophil cationic protein in upper airway disease. Curr Opin Allergy Clin Immunol 2012; 12: 18-23.
43. Jiang XD, Li GY, Li L, Dong Z, Zhu DD: The characterization of IL-17A expression in patients with chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2011; 25:e171-e175.
44. Shen Y, Pan CK, Tang XY, Yang YC, Ke X, Kou W, Wang XQ, Hong SL: Significance of interleukin-17A in patients with nasal polyposis. Asian Pac J Allergy Immunol 2011; 29: 169-175.
45. Molet SM, Hamid QA, Hamilos DL: IL-11 and IL-17 expression in nasal polyps: relationship to collagen deposition and suppression by intranasal fluticasone propionate. Laryngoscope 2003; 113: 1803-1812.
46. Shen Y, Tang XY, Yang YC, Ke X, Kou W, Pan CK, Hong SL: Impaired balance of Th17/Treg in patients with nasal polyposis. Scand J Immunol 2011; 74: 176-185.
47. Camporeale A, Poli V: IL-6, IL-17 and STAT3: a holy trinity in auto-immunity? Front Biosci 2012; 17: 2306-2326.
48. Moon HG, Kang CS, Choi JP, Choi DS, Choi HI, Choi YW, Jeon SG, Yoo JY, Jang MH, Gho YS, Kim YK: Acetyl salicylic acid inhibits Th17 airway inflammation via blockade of IL-6 and IL-17 positive feedback. Exp Mol Med 2013; 45:e6.
49. Virchow R: Die krankhaften Geschwulste: 30 Vorlesungen, geh. wahrend d. Wintersemesters 1862-1863 and. Univ. zu Berlin. Stumen, Myome, Neurome, Angiome, ed 1. Berlin, Hirschwald, 1865, vol 2, pp 106-169.
50. Demaria M, Poli V: Pro-malignant properties of STAT3 during chronic inflammation. Oncotarget 2012; 3: 359-360.
51. Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R, Briggs J, Karras J, Cress WD, Pardoll D, Jove R, Chen J, Yu H: Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 2005; 25: 7432-7440.
52. Niu G, Shain KH, Huang M, Ravi R, Bedi A, Dalton WS, Jove R, Yu H: Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res 2001; 61: 3276-3280.
53. Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T, Wasik MA: STAT3-and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci USA 2005; 102: 6948-6953.
54. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B: Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci 2009; 1171: 59-76.
55. Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, Agarwal MG: Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem 2010; 58: 2095-2099.
56. Fossey SL, Bear MD, Lin J, Li C, Schwartz EB, Li PK, Fuchs JR, Fenger J, Kisseberth WC, London CA: The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer 2011; 11: 112.
57. Lin L, Hutzen B, Li PK, Ball S, Zuo M, De Angelis S, Foust E, Sobo M, Friedman L, Bhasin D, Cen L, Li C, Lin J: A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia 2010; 12: 39-50.
58. Onimoe GI, Liu A, Lin L, Wei CC, Schwartz EB, Bhasin D, Li C, Fuchs JR, Li PK, Houghton P, Termuhlen A, Gross T, Lin J: Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs 2012; 30: 916-926.
59. Couto JI, Bear MD, Lin J, Pennel M, Kulp SK, Kisseberth WC, London CA: Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines. BMC Vet Res 2012; 8: 244.